We designed a prospective study to assess the time course and evolution of hepatitis C virus (HCV) infection in 152 patients who underwent a liver transplantation (LT) in our institution. Forty-four recipients (29%) were infected by HCV after transplantation: 40 who developed recurrent infection after LT and four who acquired infection during or after LT. No differences were found in survival actuarial rates at 1, 2, and 4 years after transplantation for patients infected by HCV vs. noninfected ones. Graft hepatitis occurred in 66% of HCV-infected recipients: 18 developed chronic active hepatitis (10 of them with intense fibrosis) and 2 developed cirrhosis during the follow-up. Infection by the HCV-1b genotype was found in 79% of the infected recipients and in 100% of those in whom histologic evolution was worst. Fourteen grafts were lost in 44 HCV-infected recipients, in comparison with 12 in 108 HCV-negative patients (P Å .007), mostly because of chronic rejection. HCV infection did not affect life expectancy in the midterm follow-up for LT patients. However, it was often associated with the occurrence of early and severe graft hepatitis and with a higher incidence of graft loss due to chronic rejection.
Liver transplantation (LT) is considered the best therapeutic hepatitis has varied widely [9, 10] . Furthermore, the clinical and histologic consequences of recurrent HCV infection on the option for the treatment of end-stage liver diseases [1] . The progressive improvement of the results of LT during the past viability of the liver grafts and their recipients remain to be adequately established. decade has created in most institutions an unbalanced ratio between the limited number of grafts available for transplanta-
The aim of our study was to analyze the frequency, time course, and short-and long-term consequences of HCV infection and the growing number of potential recipients. In this setting, some authorities have suggested careful analysis of tion following LT. Our particular interest was in the influence of HCV infection on the survival of patients and their grafts cost/benefit ratios of LT for some liver diseases, particularly those able to recur in the graft [2] . Recurrence of primary and the evolution of liver histology in HCV-infected recipients vs. noninfected ones. liver diseases, especially those of viral origin, is becoming an important threat to LT patients. Evidence of the high risk of severe recurrent disease and substantial mortality associated Patients and Methods with hepatitis B virus (HBV) reinfection in patients undergoing transplantation for chronic HBV infection has led some institu-
Patient Population
tions to no longer consider patients with hepatitis B for liver transplantation [3, 4] .
From July 1989 to June 1993, 175 adult patients underwent their first LT in our institution. Patients were excluded from Hepatitis C virus (HCV) -related liver diseases have become a common indication for LT worldwide [5] . Moreover, patients the present study if they died in the first 72 hours after LT (n Å 6), received a renal transplantation simultaneously (n Å 5), noninfected with HCV prior to hepatic transplantation can also acquire this infection following LT [6, 7] . Recurrence of HCV did not have appropriate liver and/or serum samples obtained for microbiological and pathological analysis (n Å 7), or had, infection has been shown to be a nearly universal complication following LT [6, 8] , but the incidence of recurrent histologic before or after the transplantation, coinfection with hepatitis B virus (HBV) and HCV (n Å 5). Clinical and histologic data as well as serum samples for virological analysis were prospectively collected from the remaining 152 patients, whose mean blood levels of 200 -300 ng/mL (measured by radioimmunoasby HCV, liver biopsies were performed by protocol once a year. All liver biopsy results were reviewed by two pathologists. say) in the first weeks after transplantation and 100 -150 ng/mL thereafter. Rejection episodes were treated with 1 g of methylprednisolone during 3 consecutive days, and if this Definitions failed, with OKT3 monoclonal antibodies. Management of immunosuppression was not modified at the time of documented HCV infection was defined by the detection of HCV-RNA recurrence or ''de novo'' acquisition of HCV infection.
by nested PCR in serum samples. Recurrent HCV infection Antimicrobial prophylaxis consisted of administration of was diagnosed after transplantation when HCV-RNA was denorfloxacin and nystatin or fluconazole during the first 4 weeks tected in a recipient who also tested positive for HCV-RNA after transplantation and cotrimoxazole thrice weekly during before LT. On the contrary, ''de novo'' HCV infection was the first 6 months. In addition, ganciclovir was administered considered when HCV-RNA was detected in a posttransplantato seronegative recipients of a graft from a seropositive donor tion serum sample but not before transplantation. and to seropositive recipients treated with OKT3.
Graft hepatitis was defined by the presence of hepatocyte necrosis and portal or lobular infiltration by mononuclear cells. Acute and chronic rejection was defined according to internaSerology tionally accepted criteria [12] . We were extremely careful in diagnosing graft hepatitis in the presence of histologic signs Presence of antibodies to HCV was tested for with a secondof acute rejection, above all if no relevant lobular infiltrate, generation ELISA (Ortho Diagnostics, Raritan, NJ), and posi-''piecemeal necrosis,'' or fibrosis existed. When both acute tive results were confirmed by a second-generation recombirejection and hepatitis were suspected, management included nant immunoblot assay (RIBA; Ortho Diagnostics) that detects an increase in immunosuppression and repetition of liver biopsy antibodies against epitopes located in the capsid (c22) and in within the subsequent few days to confirm the presence of graft nonstructural proteins (c33, c100-3, 5-1-1). We tested for the hepatitis. Hepatitis was further classified as chronic persistent presence of antibodies to HCV just before the transplantation hepatitis (CPH), chronic active hepatitis (CAH), and lobular and every 3 months during the first year after surgery. hepatitis, as previously described by Bianchi et al. [13] . Graft hepatitis was scored according to the histologic activity index HCV-RNA Detection described by Knodell et al. [14] .
Separation of serum was done within 3 hours of collection, and then the serum sample was stored at 070ЊC. HCV-RNA Statistical Analysis from 100 mL of serum was extracted by the guanidium thyociaActuarial rates of graft hepatitis and of patient and graft nate -phenol-chloroform method and reverse-transcribed into survival were calculated by the Kaplan-Meier method. ComcDNA. PCR was performed as a two-step reaction with two parisons between actuarial survival rates were made with the pairs of nested primers corresponding to a fragment of the 5 log-rank test. In the analysis of the time free of graft loss, data untranslated region, as described elsewhere [6, 7] . Amplificaon patients were censored at their deaths. An unpaired Student's tion products were electrophoresed on a 2% agarose gel (Nu- 
Infection by HCV HCV Genotyping
Patients were categorized into two groups on the basis of HCV genotype was determined with a line-probe genotyping the presence of HCV-RNA after LT. Forty-four recipients assay (INNO-LiPA HCV, Innogenetics, Zwijnarde, Belgium).
(29%) were infected by HCV after transplantation. In all 44 This assay is based on the utilization of biotinylated primers HCV-infected individuals, HCV-RNA was detected by day 90 and the hybridization to oligonucleotides directed against the following transplantation, and they remained positive thereafvariable region of 5 untranslated region, immobilized as paralter. HCV viremia was not detected in the remaining 108 palel lines on membrane strips [11] .
tients. As is shown in table 1, apart from the presence of HCV infection, the groups did not differ in terms of the most important variables influencing graft and patient viability folHistology lowing LT. The 108 HCV-negative recipients were given transplants Hepatic allograft biopsies were performed for all patients when liver test results became abnormal, and in those infected because of alcoholic cirrhosis (n Å 51), primary biliary cirrho-/ 9c43$$ja25 11-25-97 11:11:03 cida UC: CID second-generation ELISA from the third month after transData shown are numbers (%) of patients, except as otherwise indicated.
plantation onward. None of the 108 posttransplantation PCRnegative individuals had detectable antibodies beyond day 90 after transplantation. sis (n Å 26), chronic HBV infection (n Å 10), sclerosing cholangitis (n Å 6), cirrhosis of unknown etiology (n Å 5), autoimMortality mune hepatitis with cirrhosis (n Å 6), and hepatocellular carcinoma (n Å 4). The 44 HCV-positive recipients underwent Forty-seven of the 152 patients (31%) died during the follow-LT because of cirrhosis attributable to HCV (n Å 36), endup, including 11 of the 44 (25%) infected by HCV. As shown stage liver disease due to HCV infection and alcoholism in figure 1 , the overall actuarial survival rates among HCV-(n Å 3), primary biliary cirrhosis (n Å 2), acute liver failure infected individuals were 84%, 81%, and 74% at 1, 2, and (n Å 1), liver hydatidosis (n Å 1), and cryptogenic cirrhosis 4 years after liver transplantation and were not significantly (n Å 1).
different from those among noninfected recipients (70%, 69%, and 65%, respectively). Causes of death are shown in table 2. In only one case Moreover, when only patients with a follow-up longer than 1 year were could be the consequence of HCV transmission through the liver graft or blood products administered during the surgical analyzed, hepatitis appeared in 76% of HCV-infected individuals (28 of 37). Actuarial rates of occurrence of graft hepatitis in procedure.
Actually, three of these four recipients received a transplant this group were 48%, 70%, and 83% at 1, 2, and 4 years after transplantation, respectively (figure 2). The mean ({SD) time in the period (July 1989 to March 1990) in which serological tests for the diagnosis of HCV infection were not available.
from LT to the first evidence of graft hepatitis in HCV-infected recipients was 316 { 242 days (range, 57-814 days). Overall, 19 patients underwent LT in our center during this period; the incidence of ''de novo'' HCV infection from unFrom a histologic point of view, at the time of diagnosis of graft hepatitis, 10 of the 29 patients had lobular hepatitis, 6 had screened liver grafts and blood was then 15% (three cases). In contrast, of the 105 HCV-RNA-negative recipients who under-CPH, and 13 had CAH. Only three of the patients who developed histologically evident lobular hepatitis recovered completely durwent LT after screening began for the presence of HCV antibodies in all organ and blood donors, only one (1%) became ing the follow-up. None of the patients with chronic hepatitis / 9c43$$ja25 11-25-97 11:11:03 cida UC: CID showed significant histologic improvement. Moreover, 10 patients Genotype 1b (HCV-1b) was the predominant type of HCV in our recipients and was found in 34 of the 44 individuals, developed CAH with severe fibrosis ( §3 on the scale of fibrosis in the histologic activity index of Knodell et al. [14] ) or cirrhosis followed by type 1a (9 patients) and type 3 (1 patient). Twentythree of 34 HCV-1b-infected patients had graft hepatitis re-(n Å 2) at a mean ({SD) of 552 { 448 days (range, 153-1603 days) after LT; remarkably, 7 cases developed before the end of vealed by their last available biopsy, in comparison with only 5 of 10 non-1b-infected recipients (P Å .17). Moreover, all 12 the first year after transplantation.
The histologic picture corresponding to the last available patients with CAH and severe fibrosis or cirrhosis were infected by the 1b genotype. biopsy for the 44 HCV-infected recipients is shown in table 3. The mean histologic activity index score in the recipients with Graft hepatitis was a largely asymptomatic complication in our recipients. Seven patients developed jaundice at the time graft hepatitis was significantly higher in the last available biopsy (9.8 { 3.6; range, 3 -17) than when graft hepatitis was graft hepatitis was diagnosed. In 20 patients an asymptomatic increase in serum aminotransferase activity, with mild cholestafirst diagnosed (7.5 { 3.3; range, 3 -15) (P õ .05). The median time elapsed from the first biopsy showing hepatitis to the last sis, was the only sign accompanying the appearance of HCVrelated hepatitis. For the remaining two patients the diagnosis available biopsy was 262 { 171 days.
of graft hepatitis was made at autopsy (CAH) and routine liver biopsy (CPH), respectively, without concomitant abnormalities noted in liver function tests. Mean aspartate and alanine amino- 
Graft Survival and Causes of Graft Loss
Chronic rejection 2 1 Recurrence of carcinoma 3 1 Fourteen grafts were lost among 44 HCV-infected recipients virus (P Å .09 for the difference in recipients and P Å .027 or CAH graft hepatitis. The recipient who received a second transplant as a consequence of HCV-related graft cirrhosis defor grafts).
Posttransplantation hepatitis was diagnosed before the develveloped CAH in the new graft after a follow-up of 213 days. Eleven HCV-negative recipients were given new transplants opment of chronic rejection in 9 HCV-infected grafts (lobular hepatitis in 2, mild CAH in 4, and severe CAH in 3) and for arterial thrombosis (n Å 1), HBV-related hepatitis (n Å 2), and chronic rejection (n Å 8). simultaneously in an additional recipient with CPH. In only one HCV-infected graft, chronic rejection appeared without histologic evidence of graft hepatitis. No significant differences Discussion in the histologic score were found between those HCV-infected grafts that developed chronic rejection vs. those that did not.
The current study shows that HCV infection recurs in virtuEight HCV-infected recipients were given second transplants ally all patients after transplantation. Moreover, a careful search because of thrombosis of the hepatic artery (n Å 1), chronic for HCV-RNA by PCR during the first weeks after transplantarejection with CAH (n Å 5), chronic rejection with CPH tion showed that recurrence of HCV infection occurred very (n Å 1), and HCV-related cirrhosis (n Å 1). In addition, two early following transplantation. The origin of recurrent HCV HCV-infected individuals received a third and a fourth liver infection is not fully understood. Extrahepatic sites of viral graft because of the reappearance of chronic rejection. In all replication are well established for HBV and are implicated in cases but one, chronic rejection was accompanied by lobular the recurrence of the infection in hepatitis B surface antigenpositive liver transplant recipients [15] . Peripheral blood mononuclear cells have been shown to contain negative-stranded Table 3 . Liver histology corresponding to the last available biopsy HCV-RNA [16] , and HCV RNA has also been found in a of HCV infection, it is noteworthy that we were able to identify * Grade 3 in the histologic activity index of Knodell et al. [14] .
37 of 40 HCV-infected candidates before LT by means of the / 9c43$$ja25 11-25-97 11:11:03 cida UC: CID detection of antibodies to HCV by second-generation ELISA HCV infection during transplantation, we were not able to confirm previous data that suggested that LT patients with ''de novo'' and immunoblot assay, confirming the suggestion in our previous experience that a proper HCV serology identifies a high HCV infection more frequently developed hepatitis in the graft than did patients with recurrent infection [20] . proportion of HCV-infected LT candidates [18] . In all recipients who tested positive for HCV before transplantation, sero-
The reported incidence of graft hepatitis in HCV-infected recipients has varied widely, from 14% to 100%. Most authors positivity continued after transplantation. However, among individuals who acquired HCV infection in association with liver have considered graft hepatitis induced by HCV as a relatively benign and slowly progressive process. Ferrel et al. [20] retransplantation, only one of four developed antibodies to HCV, which is in agreement with previous reports that found a low ported the incidence of HCV-induced graft hepatitis among 43 HCV-infected recipients to be 41%, and only four of them seroconversion rate in this particular population [19] .
Our data confirm most previous reports, usually of studies developed focal bridging fibrosis and cirrhosis. Shiffman et al.
[8] found a 100% incidence of graft hepatitis in 23 LT patients with shorter follow-ups, that HCV infection did not increase mortality among LT patients [6] [7] [8] [9] [10] . Moreover, no specific infected by HCV, but in all cases hepatitis was mild (mean histologic activity index score, 4.0 { 0.3) and did not progress cause of death was more frequently associated with posttransplantation HCV infection. Specifically, we have not found a over a mean follow-up of 22 months. On the contrary, Féray et al. [10] showed that the actuarial significant increase in mortality caused by infectious complications in recipients infected by HCV, and in only one case was rate of graft hepatitis in 79 recipients infected by HCV was 72% at 4 years, and progression to CAH occurred in 61% of HCV infection, with development of severe recurrent hepatitis in the graft, directly associated with death. the subjects within 3 years. More recently, Gane et al. [21] reported that only 12% of HCV-infected recipients who surThe most controversial issue involving HCV infection and liver transplantation is the frequency and severity of histologic vived ú6 months after transplantation had no evidence of chronic hepatitis in their most recent liver biopsy. These later hepatitis in the graft and the consequences of the infection in graft survival. Graft hepatitis, in our experience, was a very data were similar to our findings. These variations may arise from differences in the definifrequent event, developing in 76% of the individuals with a follow-up longer than 1 year. Furthermore, graft hepatitis intion of chronic hepatitis, length of follow-up, and the frequency with which graft biopsies were performed. Besides duced by HCV infection seemed to be a severe and progressive lesion in most HCV-infected recipients, as judged by a signifimethodological differences, viral and host factors have been implicated in the development and severity of posttranscant increase in the histologic activity index score. In fact, only three of 29 patients with graft hepatitis caused by HCV showed plantation hepatitis C. Viral replication was, in theory, a good explanation for the varied clinical course of recurrent HCV significant histologic improvement during the follow-up.
On the contrary, 18 HCV-infected recipients developed CAH, infection in LT patients. However, the level of viremia before as well as after transplantation has not been correlated with 10 of them with intense fibrosis, which suggested an irreversible loss of the normal architecture of the liver, and two others had significant differences in the incidence and severity of graft hepatitis [22] . cirrhosis. Because of the small number of patients who acquired / 9c43$$ja25
11-25-97 11:11:03 cida UC: CID Rejection requiring OKT3 and high-dose intravenous methylthe high incidence of recurrent infection, the severity of graft damage, especially in those infected with HCV-1b, and the prednisolone therapy for acute allograft rejection were associated with a higher incidence and earlier presentation of recurrent hepaassociation with chronic rejection seem to anticipate a poorer outcome in long-term follow-up. A better definition of the risk titis C [23, 24] . The reported influence of donor-recipient human leukocyte antigen (HLA) matching on the rate of recurrence of factors that determine which individuals are likely to develop the most severe forms of HCV-induced graft injuries should histologic HCV hepatitis after liver transplantation is an example of how host factors may influence the histologic course of HCV identify candidates for early therapeutic or prophylactic interventions. infection in these population [25] .
As other RNA viruses, HCV exists as a variety of genotypes. Phylogenetic analysis of a specific genomic region has resulted in a classification of the virus into six major genotypes and 11
In addition, donor-recipient HLA matching, which has been rate similar to that among other transplant recipients. However, / 9c43$$ja25
11-25-97 11:11:03 cida UC: CID
